Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

Guidelines for clinical practice are intended to indicate preferred approaches to medical problems as established by scientifically valid research. Double-blind placebo-controlled studies are preferable, but compassionate use reports and expert review articles are utilized in a thorough review of the literature conducted through Medline with the National Library of Medicine. When only data that will not withstand objective scrutiny are available, a recommendation is identified as a consensus of experts. Guidelines are applicable to all physicians who address the subject without regard to the specialty training or interests and are intended to indicate the preferable but not necessarily the only acceptable approach to a specific problem. Guidelines are intended to be flexible and must be distinguished from standards of care, which are inflexible and rarely violated. Given the wide range of specifics in any health-care problem, the physician must always choose the course best suited to the individual patient and the variables in existence at the moment of decision.Guidelines are developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee and approved by the Board of Trustees. Each has been extensively reviewed and revised by the Committee, other experts in the field, physicians who will use them, and specialists in the science of decision of analysis. The recommendations of each guideline are therefore considered valid at the time of their production based on the data available. New developments in medical research and practice pertinent to each guideline will be reviewed at a time established and indicated at the publication in order to assure continued validity.

[1]  G. Russell Pouchitis Following Ileal Pouch Anal Anastomosis , 2006 .

[2]  D. Jewell,et al.  Cancer surveillance in ulcerative colitis , 2005, The British journal of surgery.

[3]  S. Hanauer,et al.  Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis , 1995, Digestive Diseases and Sciences.

[4]  S. Hanauer,et al.  Hazard rates for dysplasia and cancer in ulcerative colitis , 1989, Digestive Diseases and Sciences.

[5]  G. Haber,et al.  Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using99mTc-labeled 5-ASA suppositories , 1987, Digestive Diseases and Sciences.

[6]  M. Jay,et al.  Retrograde spreading of hydrocortisone enema in inflammatory bowel disease , 1986, Digestive Diseases and Sciences.

[7]  H. Janowitz,et al.  Autoimmune hemolytic anemia in ulcerative colitis , 1979, Digestive Diseases and Sciences.

[8]  M. V. M. Frcs,et al.  Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis , 2005, Digestive Diseases and Sciences.

[9]  Alastair Forbes,et al.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. , 2004, Gastroenterology.

[10]  Noam Harpaz,et al.  Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. , 2003, Gastroenterology.

[11]  J. Lewis,et al.  Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. , 2003, Gastroenterology.

[12]  N. Harpaz,et al.  The fate of indefinite dysplasia in ulcerative colitis , 2003 .

[13]  W. Kremers,et al.  Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. , 2001, Gastroenterology.

[14]  P. Brigidi,et al.  Prophylaxis of pouchitis onset with probiotic therapy: A double‐blind, placebo‐controlled trial , 2000, Gastroenterology.

[15]  American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. , 2003, Gastroenterology.

[16]  A. Cross,et al.  Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis , 2002, American Journal of Gastroenterology.

[17]  D. Levine,et al.  A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis , 2002, American Journal of Gastroenterology.

[18]  J. Achkar,et al.  Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. , 2002 .

[19]  S. Targan,et al.  6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. , 2002, Gastroenterology.

[20]  S. Kakar,et al.  The fate of low grade dysplasia in ulcerative colitis , 2002, American Journal of Gastroenterology.

[21]  J. Bai,et al.  Budesonide enema in pouchitis—a double‐blind, double‐dummy, controlled trial , 2002, Alimentary pharmacology & therapeutics.

[22]  J. Mansfield,et al.  A double‐blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis , 2002, Alimentary pharmacology & therapeutics.

[23]  M. Stolte,et al.  Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses , 2001, Gut.

[24]  J. Achkar,et al.  A Randomized Clinical Trial of Ciprofloxacin and Metronidazole to Treat Acute Pouchitis , 2001, Inflammatory bowel diseases.

[25]  A. Weaver,et al.  Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease , 2001, Gut.

[26]  D. Jewell,et al.  Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications , 2001, Diseases of the colon and rectum.

[27]  A. Kornbluth,et al.  Difficult differential diagnoses in IBD: ileitis and indeterminate colitis. , 2001, Seminars in gastrointestinal disease.

[28]  T. Lipman,et al.  AGA technical review on parenteral nutrition. , 2001, Gastroenterology.

[29]  K. Petraki,et al.  A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. , 2001, Scandinavian journal of gastroenterology.

[30]  J. Achkar,et al.  Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. , 2001, Gastroenterology.

[31]  A. Zinsmeister,et al.  A prospective cohort study of practice guidelines in inflammatory bowel disease , 2001, American Journal of Gastroenterology.

[32]  L. Mortelmans,et al.  Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. , 2001, Gastroenterology.

[33]  W. Sandborn Rational dosing of azathioprine and 6-mercaptopurine , 2001, Gut.

[34]  K. Abrams,et al.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis , 2001, Gut.

[35]  NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. , 2001, Southern medical journal.

[36]  C. Bernstein Neoplastic and other complications of inflammatory bowel disease , 2000, Current gastroenterology reports.

[37]  L. Good,et al.  Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis , 2000, American Journal of Gastroenterology.

[38]  B. Bonaz,et al.  Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. , 2000, Gastroenterology.

[39]  R. Thisted,et al.  A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis , 2000, American Journal of Gastroenterology.

[40]  S. Targan,et al.  Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. , 2000, Gastroenterology.

[41]  A. Zinsmeister,et al.  Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival , 2000, Gut.

[42]  D. Jewell,et al.  Pharmacotherapy for inducing and maintaining remission in pouchitis. , 1998, The Cochrane database of systematic reviews.

[43]  G. May,et al.  Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. , 2000, The Cochrane database of systematic reviews.

[44]  N. Harpaz,et al.  Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. , 1999, Gastroenterology.

[45]  C. Bernstein Cancer surveillance in inflammatory bowel disease , 1999, Current gastroenterology reports.

[46]  R. Odze,et al.  Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. , 1999, Gastroenterology.

[47]  C. Bernstein ALMs versus DALMs in ulcerative colitis: polypectomy or colectomy? , 1999, Gastroenterology.

[48]  S. Wallach,et al.  Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 1999, Arthritis and rheumatism.

[49]  A. Sonnenberg,et al.  The unsolved problem of surveillance for colorectal cancer in ulcerative colitis. , 1999, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[50]  K. Shetty,et al.  The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis , 1999, American Journal of Gastroenterology.

[51]  W. Sandborn Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results , 1999, American Journal of Gastroenterology.

[52]  J. Valentine,et al.  Prevention and treatment of osteoporosis in patients with inflammatory bowel disease , 1999, American Journal of Gastroenterology.

[53]  Taylor,et al.  Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months , 1998, Alimentary pharmacology & therapeutics.

[54]  S. Hanauer,et al.  Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. , 1998, Gastroenterology.

[55]  Jacques P. Brown,et al.  Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1998 .

[56]  G. Porro,et al.  Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial , 1998, American Journal of Gastroenterology.

[57]  A. Kornbluth,et al.  Is cyclosporine as effective in chronic ul cerative colitis as in severe ulcerative colitis , 1998 .

[58]  A. Zinsmeister,et al.  Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis , 1998, Cancer.

[59]  S. Hanauer How Do I Treat Erythema Nodosum, Aphthous Ulcerations, and Pyoderma Gangrenosum? , 1998, Inflammatory bowel diseases.

[60]  S. Targan,et al.  A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. , 1997, The American journal of gastroenterology.

[61]  Jacques P. Brown,et al.  Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. , 1997, The New England journal of medicine.

[62]  P. Rutgeerts,et al.  Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. , 1997, The American journal of gastroenterology.

[63]  A. Amorosi,et al.  Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. , 1997, The American journal of gastroenterology.

[64]  P. Skipworth,et al.  Reliability of rectal biopsy in distinguishing between chronic inflammatory bowel disease and acute self‐limiting colitis , 1997, Histopathology.

[65]  J. Marshall,et al.  Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. , 1997, Gut.

[66]  K. Batts,et al.  Transdermal Nicotine for Mildly to Moderately Active Ulcerative Colitis , 1997, Annals of Internal Medicine.

[67]  S Gallivan,et al.  Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. , 1997, Journal of clinical pathology.

[68]  C. Bodian,et al.  The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. , 1996, The American journal of gastroenterology.

[69]  Å. Danielsson,et al.  Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. , 1996, Gastroenterology.

[70]  S. Targan,et al.  Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. , 1996, Gastroenterology.

[71]  A. Lavy,et al.  Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. , 1996, Gastroenterology.

[72]  M. Molinari,et al.  Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. , 1996, Archives of surgery.

[73]  N. LaRusso,et al.  Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. , 1996, Gut.

[74]  S. Hanauer,et al.  An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis , 1996, Annals of Internal Medicine.

[75]  L. Eriksson,et al.  Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential , 1995, Hepatology.

[76]  J. Marshall,et al.  Rectal aminosalicylate therapy for distal ulcerative colitis: a meta‐analysis , 1995, Alimentary pharmacology & therapeutics.

[77]  R. Newcombe,et al.  Transdermal nicotine as maintenance therapy for ulcerative colitis. , 1995, The New England journal of medicine.

[78]  D. Sachar Maintenance therapy in ulcerative colitis and Crohn's disease. , 1995, Journal of clinical gastroenterology.

[79]  A. Ekbom Cancer Risk in Inflammatory Bowel Disease , 1995 .

[80]  P. Lance,et al.  Cancer surveillance in ulcerative colitis: more of the same or progress? , 1994, Gastroenterology.

[81]  C. Williams,et al.  Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. , 1994, Gastroenterology.

[82]  H. Adami,et al.  Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. , 1994, Gastroenterology.

[83]  S. Hanauer,et al.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy. , 1994, The New England journal of medicine.

[84]  M. Kamm,et al.  Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease , 1994, The Lancet.

[85]  R G Newcombe,et al.  Transdermal nicotine for active ulcerative colitis. , 1994, The New England journal of medicine.

[86]  C. Bernstein,et al.  Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? , 1994, The Lancet.

[87]  N. Harpaz,et al.  Adenocarcinoma in strictures of ulcerative colitis without antecedent dysplasia by colonoscopy. , 1994, The American journal of gastroenterology.

[88]  N. Harpaz,et al.  Refractory pouchitis: does it reflect underlying Crohn's disease? , 1993, Gut.

[89]  H. Sacks,et al.  Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. , 1993, Journal of clinical gastroenterology.

[90]  J. H. Baron,et al.  Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day , 1992, Alimentary pharmacology & therapeutics.

[91]  B. Korelitz,et al.  Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia. , 1992, Gastroenterology.

[92]  A. Axon,et al.  Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. , 1992, BMJ.

[93]  D. Sachar,et al.  Benign and malignant colorectal strictures in ulcerative colitis. , 1992, Gut.

[94]  A. Zinsmeister,et al.  Distribution of mesalamine enemas in patients with active distal ulcerative colitis. , 1992, Mayo Clinic proceedings.

[95]  C. Holdsworth,et al.  Clinical tolerance to three 5‐aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine , 1992, Alimentary pharmacology & therapeutics.

[96]  S. Lo,et al.  Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. , 1991, Annals of internal medicine.

[97]  C. Bodian,et al.  Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. , 1991, Gut.

[98]  W. Roediger The starved colon—Diminished mucosal nutrition, diminished absorption, and colitis , 1990, Diseases of the colon and rectum.

[99]  F. D'armiento,et al.  5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. , 1990, The American journal of gastroenterology.

[100]  D. Sachar,et al.  Management of severe hemorrhage in ulcerative colitis. , 1990, American journal of surgery.

[101]  M. Milla,et al.  Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis , 1990, Diseases of the colon and rectum.

[102]  A. Axon,et al.  The role of azathioprine in the management of ulcerative colitis , 1990, Diseases of the colon and rectum.

[103]  D. Jewell,et al.  High‐Dose Methylprednisolone in the Treatment of Active Ulcerative Colitis , 1988, Journal of clinical gastroenterology.

[104]  B. Korelitz,et al.  The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. , 1990, The American journal of gastroenterology.

[105]  P. Gionchetti,et al.  Pentasa in maintenance treatment of ulcerative colitis. , 1990, Gastroenterology.

[106]  L. Sutherland Topical treatment of ulcerative colitis. , 1990, The Medical clinics of North America.

[107]  R. Haggitt Differential diagnosis of colitis. , 1990, Monographs in pathology.

[108]  J. Levine Therapy of Inflammatory Bowel Disease. New Medical and Surgical Approaches , 1990, The Yale Journal of Biology and Medicine.

[109]  S. Meltzer,et al.  6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. , 1989, Annals of internal medicine.

[110]  W. Kruis,et al.  Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial. , 1989, Gut.

[111]  J. Jass,et al.  Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. , 1989, Human pathology.

[112]  R. Phillips,et al.  Ileitis and pouchitis after colectomy for ulcerative colitis , 1989, The British journal of surgery.

[113]  P. Rutgeerts,et al.  Comparative efficacy of coated, oral 5‐aminosalicylic acid (Claversal * ) and sulphasalazine for maintaining remission of ulcerative colitis , 1989, Alimentary pharmacology & therapeutics.

[114]  A. Zinsmeister,et al.  Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. , 1989, Gastroenterology.

[115]  H. Janowitz,et al.  The "natural history" of ulcerative colitis: an analysis of the placebo response. , 1989, Journal of clinical gastroenterology.

[116]  P. Blok,et al.  Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. , 1988, Gastroenterology.

[117]  D. Present,et al.  Medical decompression of toxic megacolon by "rolling". A new technique of decompression with favorable long-term follow-up. , 1988, Journal of clinical gastroenterology.

[118]  S. Riley,et al.  Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. , 1988, Gastroenterology.

[119]  J. G. Walker,et al.  Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double‐blind comparison with sulphasalazine , 1988, Alimentary pharmacology & therapeutics.

[120]  N. Greenberger,et al.  5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. , 1988, Gastroenterology.

[121]  D. Jewell,et al.  Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. , 1988, Gut.

[122]  C. H. Mason,et al.  Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. , 1988, Gut.

[123]  Z. Fireman,et al.  Colorectal cancer in patients with ulcerative colitis. A population study in central Israel. , 1988, Gastroenterology.

[124]  D. Present,et al.  Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. , 1987, Gastroenterology.

[125]  L. Sutherland,et al.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. , 1987, Gastroenterology.

[126]  P. Cann,et al.  Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine. , 1987, Scandinavian journal of gastroenterology.

[127]  H. Appelman,et al.  Histopathology differentiates acute self-limited colitis from ulcerative colitis. , 1987, Gastroenterology.

[128]  L. Sutherland,et al.  5-Aminosalicylic Acid Enemas in the Maintenance of Remission in Distal Ulcerative Colitis and Proctitis , 1987 .

[129]  J. Heppell,et al.  Toxic megacolon , 1986, Diseases of the colon and rectum.

[130]  D. Jewell,et al.  Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. , 1986, Gut.

[131]  J. Lennard-jones,et al.  Controlled trial of bowel rest in the treatment of severe acute colitis. , 1986, Gut.

[132]  W. Kraaz,et al.  Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. , 1986, Gastroenterology.

[133]  D. Sachar,et al.  A Comparison of Multiple Synchronous Colorectal Cancer in Ulcerative Colitis, Familial Polyposis Coli, and de Novo Cancer , 1986, Annals of surgery.

[134]  A. Axon,et al.  Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. , 1985, Gut.

[135]  G. Järnerot,et al.  Intensive intravenous treatment of ulcerative colitis. , 1985, Gastroenterology.

[136]  C. Surawicz,et al.  Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease. , 1984, Gastroenterology.

[137]  A. Harries,et al.  Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth. , 1983, British medical journal.

[138]  M. Dew Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid , 1982, British medical journal.

[139]  J. Lennard-jones,et al.  Controlled trial of azathioprine in chronic ulcerative colitis. , 1982, British medical journal.

[140]  B. Levin,et al.  Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. , 1981, Gastroenterology.

[141]  A. Axon,et al.  Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. , 1980, Gastroenterology.

[142]  R. Weinshilboum,et al.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.

[143]  J. Waye Endoscopy in inflammatory bowel disease. , 1980, Clinics in gastroenterology.

[144]  M. Farthing,et al.  Retrograde spread of hydrocortisone containing foam given intrarectally in ulcerative colitis. , 1979, British medical journal.

[145]  S. Geller,et al.  Cancer in universal and left-sided ulcerative colitis: clinical and pathologic features. , 1979, The Mount Sinai journal of medicine, New York.

[146]  S. Truelove,et al.  FURTHER EXPERIENCE IN THE TREATMENT OF SEVERE ATTACKS OF ULCERATIVE COLITIS , 1978, The Lancet.

[147]  J. Lennard-jones,et al.  A controlled comparison of corticotropin and hydrocortisone in the treatment of severe proctocolitis. , 1977, Scandinavian journal of gastroenterology.

[148]  H. Spiro,et al.  A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitis. , 1975, Gastroenterology.

[149]  B. Levin,et al.  A controlled trial of azathioprine in the management of chronic ulcerative colitis. , 1975, Gastroenterology.

[150]  D. Jewell,et al.  Intensive intravenous regimen for severe attacks of ulcerative colitis. , 1974, Lancet.

[151]  S. Truelove,et al.  A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin) , 1973, Gut.

[152]  F. Klion,et al.  Fate of the rectum and distal colon after subtotal colectomy for ulcerative colitis. , 1969, Gut.

[153]  S. Truelove,et al.  Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium; a report on a controlled therapeutic trial. , 1958, British medical journal.

[154]  S. Truelove,et al.  Cortisone in ulcerative colitis; final report on a therapeutic trial. , 1955, British medical journal.

[155]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .